bluebird bio, Inc.
NASDAQ: BLUE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Andrew Obenshain
- Employees
- 248
- Headquarters
- Cambridge, United States
- IPO year
- 2013
- Market cap
- $48.7M
- Website
- https://www.bluebirdbio.com
Loading BLUE…
Loading profile data…Frequently asked questions about BLUE
What does bluebird bio, Inc. (BLUE) do?
bluebird bio, Inc. is a biotechnology firm that concentrates on the discovery, development, and commercialization of innovative gene therapies. These pioneering treatments are aimed at debilitating genetic conditions. Among its leading investigational therapies for severe inherited diseases are betibeglogene autotemcel (beti-cel), intended for p...
Where does BLUE trade?
bluebird bio, Inc. (BLUE) trades on the NASDAQ Global Select.
What sector is BLUE in?
bluebird bio, Inc. (BLUE) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of bluebird bio, Inc.?
Andrew Obenshain is the chief executive officer of bluebird bio, Inc. (BLUE).
Where is bluebird bio, Inc. headquartered?
bluebird bio, Inc. is headquartered in United States.
Does BLUE pay a dividend?
bluebird bio, Inc. (BLUE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BLUE go public?
bluebird bio, Inc. (BLUE) completed its initial public offering in 2013.